Clinical trials: Moxifloxacin, open to volunteers
Multidrug- and Rifampicin-resistant Tuberculosis
BPaL(M) Regimen for the Treatment of MDR/RR-TB
The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB…
- Trial name
- NCT05381194
- Testing
- BPaL(M) regimen
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Asan Medical Center
Contraception
International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)
The combined oral contraceptive (COC) containing estetrol (E4) and drospirenone (DRSP) (E4/DRSP) is a novel oral contraceptive containing a fixed dose of E4 (14.2 mg) and DRSP (3 mg).
- Trial name
- INAS-SEECS (NCT06186271)
- Where
- Germany
- Volunteers
- 68,100 people
- Sponsor
- Center for Epidemiology and Health Research, Germany
Tuberculosis
Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
This study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in TB children are different from adults.
- Trial name
- NCT03625739
- Testing
- anti-tuberculosis drug
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Beijing Children's Hospital
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Triple Negative Breast Cancer
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic triple-negative breast cancer randomised to treatment with standard chemotherapy plus moxifloxacin or placebo.
- Trial name
- NCT04722978
- Testing
- Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Sun Yat-Sen University Cancer Center
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Healthy Participants
A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants
This study is being done to see how KRP-S124 affects the electrical activity of the heart (known as the QTc interval [QT interval corrected for heart rate]) in healthy volunteers.
- Trial name
- NCT07919314
- Testing
- KRP-S124 Low Dose, Moxifloxacin, KRP-S124 Medium Dose
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kyorin Pharmaceutical Co.,Ltd
Brucellosis, Osteoarticular Brucellosis
All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis
Brucellosis is a globally distributed zoonosis with persistent clinical management challenges. The World Health Organization (WHO)-recommended doxycycline-rifampin (DOX-RIF) dual regimen may drive rifampin-associated…
- Trial name
- BRUCE-O (NCT07887152)
- Testing
- Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin)
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
Healthy Volunteers, Safety After Oral Intake
Effects of Energy Drinks on Cardiovascular Endpoints
This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.
- Trial name
- NCT07212803
- Testing
- Energy Drink B
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of the Pacific
Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This is a Phase 3, randomized, open-label, active-controlled, multicenter trial evaluating the efficacy, safety, and tolerability of quabodepistat-containing regimens for the treatment of rifampicin-resistant or…
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- Bedaquiline, Quabodepistat, Pretomanid
- Where
- 42 sites in China, Georgia and 8 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with…
- Conditions
- Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- Trial name
- NCT07170800
- Testing
- JDB0131 100mg, JDB0131 200mg, Delamanid (D)
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Endocarditis Infective
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
Non-inferiority trial to determine whether partial oral treatment is non-inferior to OPAT(Outpatient parenteral therapy) in patients diagnosed with infective endocarditis
- Trial name
- OraPAT-IEGAMES (NCT05398679)
- Testing
- Cefaclor, Ciprofloxacin Tablets, Ciprofloxacin Injection
- Where
- 20 sites in Spain
- Volunteers
- 360 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Cataract, Postoperative Endophthalmitis
Intracameral Levofloxacin Versus Moxifloxacin After Cataract Surgery
This randomized study aims to compare the safety and efficacy of intracameral levofloxacin versus intracameral moxifloxacin administered at the end of phacoemulsification cataract surgery.
- Trial name
- NCT07850414
- Testing
- Levofloxacin, Moxifloxacin
- Volunteers
- 93 people
- Sponsor
- Assiut University
Pediatric ALL
Pharmacokinetics of Drugs Administered to Children
This is a prospective study of children <21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver.
- Trial name
- NCT03481881
- Testing
- Standard of care drug
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Duke University
Odontogenic Infection, Maxillofacial Infection
Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes
Investigators are conducting a trial to compare moxifloxacin against clindamycin for dental infections that spread to the face and jaw.
- Conditions
- Odontogenic Infection, Maxillofacial Infection, Cellulitis, Cellulitis of Face
- Trial name
- NCT07810244
- Testing
- Clindamycin, Moxifloxacin (400 mg)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Nishtar Medical University
Helicobacter Infection
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
- Trial name
- NCT02373280
- Testing
- 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole), 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy), 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Non-cystic Fibrosis Bronchiectasis (NCFBE)
Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese Participants
This study is a concentration-QTc interval clinical study of HSK31858 tablets in healthy participants.
- Trial name
- NCT07915024
- Testing
- HSK31858 tablet, Moxifloxacin
- Where
- China
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Infections Joint Prosthetic
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis.
- Trial name
- RIFACute (NCT05902221)
- Testing
- amoxicillin or moxifloxacin, amoxicillin or moxifloxacin + rifampicin
- Where
- 13 sites in France
- Volunteers
- 235 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM)
A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
The treatment of rifampicin-resistant/multidrug-resistant pulmonary tuberculosis (RR-TB) is characterized by a long treatment course, a high incidence of adverse reactions, a low cure rate, and a high recurrence rate.
- Conditions
- Rifampicin-resistant/Multidrug-resistant Pulmonary Tuberculosis, Type 2 Diabetes Mellitus (T2DM), Pretomanid
- Trial name
- NCT07191834
- Volunteers
- 60 people
- Sponsor
- Wuhan Pulmonary Hospital